PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptNIH Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Cancer Res. Author manuscript; available in PMC Oct 1, 2009.
Published in final edited form as:
PMCID: PMC2561223
NIHMSID: NIHMS64395
Cell cycle dependent variation of a CD133 epitope in human embryonic stem cell, colon cancer and melanoma cell lines
Marie Jaksch, Jorge Múnera, Ruchi Bajpai,# Alexey Terskikh, and Robert G. Oshima*
Tumor Development Program, Cancer Research Center, The Burnham Institute for Medical Research, La Jolla, CA
* corresponding author: The Burnham Institute for Medical Research, 10901 N. Torrey Pines Road, La Jolla, CA 92035, Email: rgoshima/at/burnham.org, Phone: 858 646 3147
#current address: CCSR 3130, Chemical and Systems Biology, 269 Campus Drive, Stanford University, CA 94305
CD133 (Prominin1) is a pentaspan transmembrane glycoprotein expressed in several stem cell populations and cancers. Reactivity with an antibody (AC133) to a glycoslyated form of CD133 has been widely used for the enrichment of cells with tumor initiating activity in xenograph transplantation assays. We have found by fluorescence-activated cell sorting that increased AC133 reactivity in human embryonic stem cells, colon cancer and melanoma cells is correlated with increased DNA content and reciprocally, that the least reactive cells are in the G1/G0 portion of the cell cycle. Continued cultivation of cells sorted on the basis of high and low AC133 reactivity results in a normalization of the cell reactivity profiles indicating that cells with low AC133 reactivity can generate highly reactive cells as they resume proliferation. The association of AC133 with actively cycling cells may contribute to the basis for enrichment for tumor initiating activity.
Tumors may be composed of a hierarchy of cells in which only a subset are responsible for self renewal, while the remainder may not be tumorgenic. Putative cancer stem cells (CSCs) have been identified in multiple types of human cancers by their ability to initiate tumors in immune compromised mice (1). However, some tumor cells that do not express CD133 are capable of self-renewal and are tumorigenic (2-4) and not all human tumor cell lines that are capable of generating tumors, at low cell numbers are AC133 positive. Never the less, markers that allow enrichment for CSCs from whole tumor tissues are essential for the purification, characterization and eventual targeting of CSCs. A very specific antibody designated AC133 (5), against a glycosylated form of the cell surface protein CD133 (Prominin1) has been widely used to enrich for CSC (6). Reaction with the AC133 antibody (Miltenyi Biotech) is not identical with CD133 protein detection but rather appears to be due to a glycosylated form of membrane associated CD133 (6). The AC133 epitope is expressed on some human stem and progenitor cells but is not present on mouse cells (6). Cells that react with AC133 are reported to be more likely to form tumors in transplantation tests than cells that are negative (7-10). AC133 reaction has been used to enrich for cells with tumor initiating activity from human brain tumors, colon cancers and prostate cancer (7-9).
We have found that in culture, AC133 reactivity is correlated with the cell cycle DNA profile of colon cancer, melanoma and human embryonic stem cells. In some cell types, differential AC133 expression may more accurately reflect cycling cells rather than a differentially expressed stable stem cell lineage marker.
Cell culture
The human colon epithelial cancer cell line Caco2 was obtained from American Type Culture Collection (ATCC, Manassas, VA). Caco2 cells at passage 10 were infected with a Lentivirus reporter vectors that contain the mouse Melk promoter driving enhancer green fluorescent protein (MELK-GFP) (11) or a control PGK promoter driven H2B-GFP vector. Individual clones were isolated and two of the clones were used for further experiments. Caco2 cells were cultured as suggested by the supplier. Caco2 cells were cultured, 2 days (sub-confluent), 3 days (confluent) and 14 days (post-confluent) to generate differentiated cells. The melanoma cell line WM115, provided by Boris Fichtman and Zeev Ronai (Burnham Institute for Medical Research, La Jolla, CA), was cultured in RPMI 1640 supplemented with 10% fetal bovine serum. The H9 hES cells were provided by Brandon Nelson and Mark Mercola, (Burnham Institute for Medical Research La Jolla, CA). They were cultivated with mouse embryo fibroblast feeder cell conditioned medium supplemented with bFGF as described (12). The undifferentiated state of the hES cells was routinely monitored by staining for Oct4 and other hES markers.
Immunocytochemistry
Single cell suspensions were applied to glass slides with a Shandon Cytospin 3 centrifuge at 500 rpm for 5 minutes. The cells were fixed for 5 minutes in 2% paraformaldehyde (Sigma-Aldrich, St. Louis, MO) at room temperature, washed twice in PBS then blocked with 1.5% normal goat serum for 1 hour at room temperature. The cells were incubated with a 1:10 dilution of the primary antibody (anti CD133-PE, AC133, Miltenyi Biotec, Auburn, CA) at 37°C for 1 hour and subsequently washed twice with 0.1% Tween 20 (Sigma-Aldrich, St. Louis, MO) in PBS and twice with PBS. The primary antibody was detected with Alexa 568-conjugated goat anti mouse IgG 1:100 (Invitrogen, Carlsbad, CA) and nuclei were stained with DAPI. The stained cells were mounted in Vectashield mounting medium (VECTOR, Burlingame, CA).
Flow cytometry analysis
AC133 reaction was identified by direct immunofluorescent staining using the AC133 mouse monoclonal antibody direct conjugated with phycoerythrin (PE). All cells were stained according to manufacturer's recommendations. In brief, 2×105 live cells were suspended in 100μl of buffer (0.5% FCS and 2mM EDTA) and stained for 10 minutes at 4°C with 10μl of the AC133 antibody (1:11). Cells were analyzed for PE and GFP expression by flow cytometry on a FACSort cytometer (Becton Dickinson, San Jose, CA). 10,000 events were acquired and analyzed using FlowJo software.
Cell cycle analysis
DNA in MELK-GFP expressing Caco2 cells was stained using Hoechst 33342 (Invitrogen, Carlsbad CA) while WM115 and hES cells were stained with Draq5 (Biostatus Ltd, Leicestershire, UK). For the Hoechst 33342 staining 2-3×105 cells, previously stained for AC133, were washed 1× in wash buffer (0.5% FCS and 2mM EDTA in PBS). Cells were resuspended in 250μl of culture media (DMEM) and Hoechst 33342 was added to a final concentration of 15ug/ml. Cells were incubated at 37°C for 90 minutes. For the Draq5 staining 1×105 cells, previously stained for AC133, were washed 1× in wash buffer. The cells were resuspended in DMEM and Draq5 at a final concentration of 10μM. Cells stained with Hoechst 33342 were analyzed on a FACSDiVa flow cytometer (Becton Dickinson) and cells stained with Draq5 were analyzed on a FACSort cytometer (Becton Dickinson). All FACS data was analyzed using FlowJo software.
FACSort
For sorting cells expressing AC133, the cells were removed from the culture dish with 0.05% trypsin and 0.02% EDTA (Invitrogen, Carlsbad, CA), washed in PBS containing 1% FCS, stained as described above and resuspended at 106 cells per ml in the same buffer. The cells were filtered through a 35μM nylon filter prior to FACSort. Sorting was performed on a FACSDiVa flow cytometer (Becton Dickinson). Side and forward scatter profiles and propidium iodide (PI) staining were used to eliminate cell doublets and dead cells. The top ten percent of the AC133 reactive cells and the AC133 negative cells were collected. An aliquot was removed at the end of the sort and reanalyzed to evaluate purity.
Colony formation assay
Caco2 cells sorted on AC133 reactivity were cultured in a 24-well plates at concentrations of 100, 300, 1000 and 5000 cells per well, in triplicates. After 7 days the cells were fixed in methanol, stained with giemsa stain and counted with a dissection microscope at 10× magnification.
Proliferation assay
AC133 high and negative sorted cells were plated at a concentration of 50, 500 and 5000 cells per well in duplicate. Cells were cultured for 1, 2 or 3 days. The cells were washed 2× in PBS before they were frozen at -70°C in the 96-well plate. The CyQUANT Cell Proliferation Assay Kit (Invitrogen, Carlsbad, CA) was used according to manufacturer's instruction.
Microarray analysis
Total RNA from AC133 high and negative sorted Caco2 and WM115 cells was extracted using the TRI Reagent (Molecular Research Center, Inc., Cincinnati, OH) according to the manufacturer's protocol. Two samples each of two cell lines were analyzed as biological duplicates. Labeled cRNA was prepared from 500 ng RNA using the Illumina® RNA Amplification Kit from Ambion (Austin, TX, USA). The Biotin labeled cRNA (750 ng) was hybridized 18 hr at 58°C to the HumanRef-8 v2 Expression BeadChip (>22,000 gene transcripts; Illumina, San Diego, CA, USA) according to the manufacturer's instructions. BeadChips were scanned with an Illumina BeadArray Reader and hybridization efficiency was monitored using BeadStudio software (Illumina). BeadStudio software was used to normalize and to quality control the data. To identify statistically significant changes the data were evaluated by GeneSpring software. A volcano plot was used to identify genes with changed a least 2 fold and had reproducibility p-values of 0.05 or less. The list of genes passing these thresholds was compared to publically available data using the Nextbio search engine. Complete primary data are available though the Gene Expression Omnibus support by the National Center for Biotechnology Information as GEO accession number (GSE11757).
AC133 expression in Caco2 and hES cells
A screen of seven human cell lines for AC133 expression revealed three that were positive. We did not detect reaction with MDA-MB231, MCF7, Du145, or U87 cells. FACS analysis and immunofluorescence staining of Caco2 and H9 hES cells detected high levels of the AC133 epitope (Fig. 1). 94% and 70% of Caco2 and hES cells respectively showed positive staining. These results confirm previous reports of AC133 reactivity on Caco2 cells (13) and hES cells (14). The human melanoma cell line WM115 was also positive (15). Interestingly, the immunoreactivity for the AC133 antigen, but not CD133 mRNA level, is reported to be down-regulated upon differentiation of Caco2 cells for 40 days (13). In our study we did not see a significant difference in AC133 expression in sub-confluent, confluent and 14 day post confluent cells (Fig. 1C).
Figure 1
Figure 1
AC133 expression in Caco2 and hES cells
AC133 expression and DNA profile in subpopulations
Fluorescence activated cell sorting (FACS) analysis of the DNA contents of AC133 reactive cells revealed that cells with greatest AC133 reaction were enriched for cells with DNA content of 4N, or even greater, in the case of hES cells (Fig. 2). When equal subpopulations of AC133+ cells (Fig. 2A) were analyzed for DNA content, the fraction of cells with 4N DNA content or greater was found to correlate with increasing AC133 reactivity, while the fraction of cells with 2N DNA (G1 and G0 portion of the cell cycle) was inversely correlated with AC133 reaction (Fig. 2B). In the cells with least AC133 binding, almost 70% of the cells contained 2N DNA content compared to only 20% of the cells with highest levels of AC133 (Fig. 2C left). Similar results were found for subcloned populations of Caco2 cells. 80% of the cells that expressed the lowest levels of AC133 showed a DNA profile similar to cells with 2N DNA content compared to only 14% of the cells expressing the highest levels of AC133. These results were also confirmed by the AC133 expression in the melanoma cell line WM115. Figure 2D summarizes the results from all three cell lines. Cell cycle profiles on cells gated on the highest 10% and the lowest 10% of AC133 expression are shown.
Figure 2
Figure 2
Correlation of AC133 reaction and DNA content
Expression of the maternal embryonic leucine zipper kinase (MELK) protein is cell cycle dependent (16). We compared the expression of a MELK-GFP reporter gene with its corresponding DNA content profile. The expression of the GFP protein from a MELK-GFP reporter gene in cloned Caco2 cells has the same correlation with DNA content as the AC133 antigen (Fig. 2C right). These data are consistent with previous reports that CD133+ cells have a much higher expression of MELK mRNA compared to autologous CD133 negative tumor cells from glioblastoma patients. Grskovic et al. documented that CD133+ cells are more mitotically active than CD133- cells after the first week of cultivation (17, 18).
Gene expression in AC133 high and negative sorted cells
The gene expression profiles for AC133 high vs. negative sorted Caco2 and WM115 cells were compared. Figure 3A and B show scatter plots from the obtained microarray data with a fold difference of 2 or more. The r2 values (r2=0.9859 and r2=0.9842) indicate high similarity in gene expression between cells sorted on extremes of AC133. An unsupervised cluster analysis of individual gene expression data sets did not distinguish AC133 reactive cells (Fig. 3C). Noteworthy, the most striking difference was the up-regulated expression of Prominin1 in AC133 high expressing cells, 15× and 9× for Caco2 and WM115 respectively. This was the only gene that was differentially expressed in both cell lines. This indicates that AC133 reaction correlates well with Prominin1 RNA. A total of only 39 Caco2 RNAs and 7 WM115 RNAs (Supplementary Table S1) were significantly different (≥ 2 fold and reproducibility p<0.05) between AC133 high and negative cell fractions.
Figure 3
Figure 3
Gene expression in AC133 high vs. negative cells
Cultivation of high and negative sorted cells
To determine the stability of AC133 antigen expression high and negative AC133 sorted Caco2 cell were cultivated. A colony formation assay showed a significant difference in colony formation frequency between the two sorted cell populations (p<0.05) (Fig. 4A). However, even though the AC133 negative cells were less likely to grow from single cells, the proliferation rate for the two cell populations were not significant different (p>0.05) (Fig. 4B). After a few passages AC133 negative cells expressed similar levels of AC133 as the starting population (Fig. 4C). Similarly, cells sorted on high expression of AC133 generated cells with less expression (Fig. 4C). Hence, continued culturing of cells with extremes of AC133 reactivity leads to redistribution of the degree of reaction. Also, the morphology of the colonies formed after cultivation is very similar between the two different subpopulations (Fig. 4D). Chang and colleagues (19) have recently showed similar results with another stem cell marker, Sca-1. In clonal populations of mouse hematopoietic progenitor cells they found that spontaneous ‘outlier’ cells with either extremely high or low expression levels of Sca-1 reconstitute the parental distribution of Sca-1 after one week. These extremes of Sca-1 expression were associated with differential gene expression consistent with increased probability of differentiation along two different lineages. However, in our study, the high and negative expressing sorted cells do not appear to belong to two distinct cell populations based on gene expression profiles. The AC133 epitope appears not to be a stable marker for a particular population of cells but rather may reflect mitotic activity. Cell cycle dependence might be one of the metastable variables contributing to transcriptome variation (15).
Figure 4
Figure 4
Colony formation, proliferation and AC133 expression in AC133 high and negative sorted cells
The cell cycle associated reactivity of AC133 is similar to the cell cycle dependent expression of CD34, a hematopoietic progenitor marker that is also commonly detected by a glycosylation dependent epitope. CD34 expression has been a valuable tool for identification and purification of human hematopoietic stem cells. However, CD34 expression in mice is not required for survival and murine hematopoiesis could be reconstituted by CD34 cells (20). Recently, Dooley et al. (21) showed that CD34 expression increased as CD34 cells shifted from quiescence to proliferation. Cultured CD34 cells up-regulate CD34 antigen expression in as little as 42 hours and CD34+ precursors lost expression in culture if they remained in G0 for more than 2 days.
Tumor initiating cells with stem-like characteristics might have differential resistance to chemotherapy or radiotherapy. CD133+ glioblastoma cells are significantly more resistant to conventional chemotherapeutic agents and resistance is correlated with higher expression of survivin, an anti-apoptotic acting protein in CD133+ cells (18, 22). However, survivin expression is cell cycle dependent, increasing in the G2/M phase of the cell cycle followed by a rapid decline in the G1 phase. The selection of AC133 reactive cells in this system might also be expected to enrich for cells with high survivin expression and thus increased resistance to apoptotic agents.
Primary human cancers are commonly heterogeneous with both host and tumor related components. The proportion of actively proliferating cancer cells varies greatly depending on the tumor and its progression. The general strategy of targeting proliferative cells of cancers is being challenged by the cancer stem cell model that may include extrapolations from the behavior of slow cycling normal stem cells. However, the essential defining characteristic of a cancer stem cell, supported by the biology of teratocarcinoma and certain leukemias, is the directional, moderating influence of differentiation to a stable benign state. AC133 reactivity may be used for enrichment for tumor initiating activity without necessarily supporting a cancer stem cell theory.
To summarize, our study indicates that within three different cell types that express AC133, the antigen expression is highest in cells with 4N DNA content and lowest in cells with 2N DNA. This is consistent with higher expression in actively proliferating cells and low expression in cells in G1 or G0. We show that cultivation of cells with the extremes of AC133 reactivity resulted in a redistribution of the antigen expression which suggests that high and low expressing cells do not belong to stable distinct populations. AC133 reactivity may be valuable for identify cells with increased tumorgenicity. However, the basis of this utility may be due to the distinction between proliferative and quiescent cells and should be used cautiously as a putative marker of a stable, distinct stem cell like population.
Acknowledgments
We thank Yoav Altman for expert technical help of the Burnham Cell Analysis Shared Resource, Roy Williams at the Burnham Bioinformatics Shared Resource for help with evaluation of the microarray data, Brandon Nelson and Mark Mercola for human ES cells and Boris Fichtman and Zeev Ronai for WM115 cells.
This work was supported by a research grant from the California Institute for Regenerative Medicine (CIRM) RS1-00283-1. MJ and RB were both supported by Postdoctoral Training Grant T2-00004 from CIRM. JM was supported by a research supplement to promote diversity in health-related research for grant PO1 CA102583 from the National Cancer Institute.
1. Ailles LE, Weissman IL. Cancer stem cells in solid tumors. Curr Opin Biotechnol. 2007;18:460–6. [PubMed]
2. Beier D, Hau P, Proescholdt M, et al. CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res. 2007;67:4010–5. [PubMed]
3. Shmelkov SV, Butler JM, Hooper AT, et al. CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. J Clin Invest. 2008;118:2111–20. [PMC free article] [PubMed]
4. Zheng X, Shen G, Yang X, Liu W. Most C6 cells are cancer stem cells: evidence from clonal and population analyses. Cancer Res. 2007;67:3691–7. [PubMed]
5. Miraglia S, Godfrey W, Yin AH, et al. A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood. 1997;90:5013–21. [PubMed]
6. Mizrak D, Brittan M, Alison MR. CD133: molecule of the moment. J Pathol. 2008;214:3–9. [PubMed]
7. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 2007;445:106–10. [PubMed]
8. Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al. Identification and expansion of human colon-cancer-initiating cells. Nature. 2007;445:111–5. [PubMed]
9. Richardson GD, Robson CN, Lang SH, Neal DE, Maitland NJ, Collins AT. CD133, a novel marker for human prostatic epithelial stem cells. J Cell Sci. 2004;117:3539–45. [PubMed]
10. Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature. 2004;432:396–401. [PubMed]
11. Nakano I, Paucar AA, Bajpai R, et al. Maternal embryonic leucine zipper kinase (MELK) regulates multipotent neural progenitor proliferation. J Cell Biol. 2005;170:413–27. [PMC free article] [PubMed]
12. Katkov II, Kim MS, Bajpai R, et al. Cryopreservation by slow cooling with DMSO diminished production of Oct-4 pluripotency marker in human embryonic stem cells. Cryobiology. 2006;53:194–205. [PubMed]
13. Corbeil D, Roper K, Hellwig A, et al. The human AC133 hematopoietic stem cell antigen is also expressed in epithelial cells and targeted to plasma membrane protrusions. J Biol Chem. 2000;275:5512–20. [PubMed]
14. Carpenter MK, Rosler ES, Fisk GJ, et al. Properties of four human embryonic stem cell lines maintained in a feeder-free culture system. Dev Dyn. 2004;229:243–58. [PubMed]
15. Monzani E, Facchetti F, Galmozzi E, et al. Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur J Cancer. 2007;43:935–46. [PubMed]
16. Gray D, Jubb AM, Hogue D, et al. Maternal embryonic leucine zipper kinase/murine protein serine-threonine kinase 38 is a promising therapeutic target for multiple cancers. Cancer Res. 2005;65:9751–61. [PubMed]
17. Grskovic B, Ruzicka K, Karimi A, Qujeq D, Muller MM. Cell cycle analysis of the CD133+ and CD133- cells isolated from umbilical cord blood. Clin Chim Acta. 2004;343:173–8. [PubMed]
18. Liu G, Yuan X, Zeng Z, et al. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer. 2006;5:67. [PMC free article] [PubMed]
19. Chang HH, Hemberg M, Barahona M, Ingber DE, Huang S. Transcriptome-wide noise controls lineage choice in mammalian progenitor cells. Nature. 2008;453:544–7. [PubMed]
20. Sato T, Laver JH, Ogawa M. Reversible expression of CD34 by murine hematopoietic stem cells. Blood. 1999;94:2548–54. [PubMed]
21. Dooley DC, Oppenlander BK, Xiao M. Analysis of primitive CD34- and CD34+ hematopoietic cells from adults: gain and loss of CD34 antigen by undifferentiated cells are closely linked to proliferative status in culture. Stem Cells. 2004;22:556–69. [PubMed]
22. Chandele A, Prasad V, Jagtap JC, Shukla R, Shastry PR. Upregulation of survivin in G2/M cells and inhibition of caspase 9 activity enhances resistance in staurosporine-induced apoptosis. Neoplasia. 2004;6:29–40. [PMC free article] [PubMed]